Keywords: Medivation, Astellas, Xtandi, Enzalutamide, Prostate cancer, USA, FDA

FDA backs Medivation and Astellas' prostate cancer drug Xtandi

Article | 03 September 2012

Print This

USA-based Medivation (Nasdaq: MDVN and Japanese drug major Astellas Pharma (TYO: 4503) say that the US Food and Drug Administration has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in